X

pharmaceuticals

Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO

CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on…

Viatris (VTRS) posts Q3 2025 results and updates 2025 guidance

Pharmaceuticals company Viatris Inc. (NASDAQ: VTRS) on Thursday reported financial results for the third quarter of fiscal 2025, and updated…

Earnings Summary: Humana Q3 2025 profit drops despite higher revenues

Humana Inc. (NYSE: HUM), a leading health and well-being company, on Wednesday reported a decline in adjusted earnings for the…

Key takeaways from Pfizer’s (PFE) Q3 2025 earnings report

Shares of Pfizer Inc. (NYSE: PFE) stayed green during midday trade on Tuesday following the company’s announcement of its third…

PFE Earnings: All you need to know about Pfizer’s Q3 2025 earnings results

Pfizer Inc. (NYSE: PFE) reported its third quarter 2025 earnings results today. Revenues were $16.7 billion, down 6% on a…

ABBV Earnings: A snapshot of AbbVie’s Q3 2025 report

Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025,…

BIIB Earnings: A snapshot of Biogen’s Q3 2025 results

Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported an increase in adjusted profit for the third quarter of 2025 when its…

Earnings Summary: Cardinal Health Q1 2026 revenue jumps 22%; raises guidance

Pharmaceuticals distributor Cardinal Health (NYSE: CAH) reported a sharp increase in revenue and adjusted earnings for the first quarter of…

Bristol Myers Squibb (BMY) Earnings: 3Q25 Key Numbers

Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2025 earnings results today. Revenues increased 3% year-over-year to $12.2 billion.…

Eli Lilly (LLY) Earnings: 3Q25 Key Numbers

Eli Lilly and Company (NYSE: LLY) reported its third quarter 2025 earnings results today. Worldwide revenue was $17.60 billion, up…

Key highlights from Merck’s (MRK) Q3 2025 earnings results

Merck & Co., Inc. (NYSE: MRK) reported its third quarter 2025 earnings results today. Total worldwide sales of $17.3 billion…

UnitedHealth Group’s Q3 2025 earnings fall despite double-digit revenue growth

Healthcare behemoth UnitedHealth Group (NYSE: UNH) announced results for the third quarter of fiscal 2025, reporting an increase in revenues…

Abbott Laboratories Q3 adj. earnings rise on higher sales; meet Street view

Abbott Laboratories (NYSE: ABT) reported higher sales and adjusted earnings for the third quarter of fiscal 2025. The healthcare company…

Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO

Kairos Pharma, Ltd. (NYSE: KAPA) is a biopharma company developing a pipeline of targeted therapies for cancer patients with high…

JNJ Earnings: Key quarterly highlights from Johnson & Johnson’s Q3 2025 financial results

Johnson & Johnson (NYSE: JNJ) reported its third quarter 2025 earnings results today. Reported sales increased 6.8% year-over-year to $24…

IPO News: MapLight Therapeutics targets $704 mln valuation in Nasdaq debut

In recent months, Wall Street has seen a surge of healthcare firms seeking to go public, as IPO activity continues…

Innovation pipeline, portfolio in focus ahead of Johnson & Johnson’s Q3 earnings

For Johnson & Johnson (NYSE: JNJ), 2025 has been a strong year, marked by an impressive financial performance that drove…

McKesson Corporation (MCK) raises FY26 earnings guidance

McKesson Corporation (NYSE: MCK), a diversified healthcare service company that operates in partnership with biopharma companies and care providers, has…

Earnings Summary: Cardinal Health reports higher Q4 earnings and flat revenues

Cardinal Health (NYSE: CAH), a leading pharmaceuticals distributor, on Tuesday reported an increase in adjusted profit for the fourth quarter…

Key highlights from Eli Lilly’s (LLY) Q2 2025 earnings results

Eli Lilly and Company (NYSE: LLY) reported its second quarter 2025 earnings results today. Worldwide revenue was $15.56 billion, up…

Eli Lilly (LLY) set to report Q2 2025 results. Here’s what to expect

Eli Lilly and Company (NYSE: LLY) had a positive start to fiscal 2025, reporting strong revenue and earnings growth for…